-
Ashkenazi A, 2008: Directing cancer cells to self-destruct with pro-apoptotic receptor agonists[J]. Nature Reviews Drug Discovery, 7, 1001-1012. doi: 10.1038/nrd2637
-
Bale S, Dias J M, Fusco M L, Hashiguchi T, Wong A C, Liu T, Keuhne A I, Li S, Woods V L, J r., Chandran K, Dye J M, Saphire E O, 2012: Structural basis for differential neutralization of ebolaviruses[J]. Viruses, 4, 447-470. doi: 10.3390/v4040447
-
Bonsignori M, Alam S M, Liao H X, Verkoczy L, Tomaras G D, Haynes B F, Moody M A, 2012: HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design[J]. Trends Microbiol, 20, 532-539. doi: 10.1016/j.tim.2012.08.011
-
Bossart K N, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern J A, Green D, Hancock T J, Chan Y P, Hickey A C, Dimitrov D S, Wang L F, Broder C C, 2009: A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection[J]. PLoS Pathog, 5, e1000642-. doi: 10.1371/journal.ppat.1000642
-
Bossart K N, Geisbert T W, Feldmann H, Zhu Z, Feldmann F, Geisbert J B, Yan L, Feng Y R, Brining D, Scott D, Wang Y, Dimitrov A S, Callison J, Chan Y P, Hickey A C, Dimitrov D S, Broder C C, Rockx B, 2011: A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge[J]. Sci Transl Med, 3, 105ra103-.
-
Bouchet J, Basmaciogullari S E, Chrobak P, Stolp B, Bouchard N, Fackler O T, Chames P, Jolicoeur P, Benichou S, Baty D, 2011: Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody[J]. Blood, 117, 3559-3568. doi: 10.1182/blood-2010-07-296749
-
Bowden T A, Aricescu A R, Gilbert R J, Grimes J M, Jones E Y, Stuart D I, 2008: Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2[J]. Nat Struct Mol Biol, 15, 567-572. doi: 10.1038/nsmb.1435
-
Bugli F, Manzara S, Torelli R, Graffeo R, Santangelo R, Cattani P, Fadda G, 2004: Human monoclonal antibody fragment specific for glycoprotein G in herpes simplex virus type 2 with applications for serotype-specific diagnosis[J]. J Clin Microbiol, 42, 1250-1253. doi: 10.1128/JCM.42.3.1250-1253.2004
-
Burton D R, Pyati J, Koduri R, Sharp S J, Thornton G B, Parren P W, Sawyer L S, Hendry R M, Dunlop N, Nara P L, a nd, 1994: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody[J]. Science, 266, 1024-1027. doi: 10.1126/science.7973652
-
Carter P J, 2006: Potent antibody therapeutics by design[J]. Nature Reviews Immunology, 6, 343-357. doi: 10.1038/nri1837
-
Casadevall A, Dadachova E, Pirofski L, 2004: Passive antibody therapy for infectious diseases[J]. Nature Reviews Microbiology, 2, 695-703. doi: 10.1038/nrmicro974
-
Chen L, Kwon Y D, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell A J, Pancera M, Tang M, Xu L, Yang Z Y, Zhang M Y, Arthos J, Burton D R, Dimitrov D S, Nabel G J, Posner M R, Sodroski J, Wyatt R, Mascola J R, Kwong P D, 2009: Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120[J]. Science, 326, 1123-1127. doi: 10.1126/science.1175868
-
Chen W, Zhu Z, Feng Y, Dimitrov D S, 2008: Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers[J]. Proc Natl Acad Sci U S A, 105, 17121-17126. doi: 10.1073/pnas.0805297105
-
Chen W, Prabakaran P, Zhu Z, Feng Y, Streaker E D, Dimitrov D S, 2012: Characterization of human IgG repertoires in an acute HIV-1 infection[J]. Exp Mol Pathol, 93, 399-407. doi: 10.1016/j.yexmp.2012.09.022
-
Chen W, Streaker E D, Russ D E, Feng Y, Prabakaran P, Dimitrov D S, 2012: Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens[J]. Biochem Biophys Res Commun, 417, 1164-1169. doi: 10.1016/j.bbrc.2011.12.089
-
Chen W, Zhu Z, Liao H, Quinnan G V, J r., Broder C C, Haynes B F, Dimitrov D S, 2010: Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins[J]. Viruses, 2, 547-565. doi: 10.3390/v2020547
-
Corti D, Suguitan A L, J r., Pinna D, Silacci C, Fernandez-Rodriguez B M, Vanzetta F, Santos C, Luke C J, Torres-Velez F J, Temperton N J, Weiss R A, Sallusto F, Subbarao K, Lanzavecchia A, 2010: Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine[J]. J Clin Invest, 120, 1663-1673. doi: 10.1172/JCI41902
-
Corti D, Voss J, Gamblin S J, Codoni G, Macagno A, Jarrossay D, Vachieri S G, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez B M, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire L F, Temperton N, Langedijk J P, Skehel J J, Lanzavecchia A, 2011: A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins[J]. Science, 333, 850-856. doi: 10.1126/science.1205669
-
Coughlin M M, Prabhakar B S, 2012: Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential[J]. Rev Med Virol, 22, 2-17. doi: 10.1002/rmv.v22.1
-
Darbha R, Phogat S, Labrijn A F, Shu Y, Gu Y, Andrykovitch M, Zhang M Y, Pantophlet R, Martin L, Vita C, Burton D R, Dimitrov D S, Ji X, 2004: Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope[J]. Biochemistry, 43, 1410-1417. doi: 10.1021/bi035323x
-
Deschacht N, De Groeve K, Vincke C, Raes G, De Baetselier P, Muyldermans S, 2010: A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire[J]. J Immunol, 184, 5696-5704. doi: 10.4049/jimmunol.0903722
-
Dimitrov D S, 2009: Engineered CH2 domains (nanoantibodies)[J]. Mabs, 1, 26-28. doi: 10.4161/mabs.1.1.7480
-
Dimitrov D S, 2010: Therapeutic antibodies, vaccines and antibodyomes[J]. Mabs, 2, 347-356. doi: 10.4161/mabs.2.3.11779
-
Dimitrov D S, 2012: Therapeutic proteins[J]. Methods Mol Biol, 899, 1-26. doi: 10.1007/978-1-61779-921-1
-
Dreyfus C, Laursen N S, Kwaks T, Zuijdgeest D, Khayat R, Ekiert D C, Lee J H, Metlagel Z, Bujny M V, Jongeneelen M, van der Vlugt R, Lamrani M, Korse H J, Geelen E, Sahin O, Sieuwerts M, Brakenhoff J P, Vogels R, Li O T, Poon L L, Peiris M, Koudstaal W, Ward A B, Wilson I A, Goudsmit J, Friesen R H, 2012: Highly conserved protective epitopes on influenza B viruses[J]. Science, 337, 1343-1348. doi: 10.1126/science.1222908
-
Du L, He Y, Zhou Y, Liu S, Zheng B J, Jiang S, 2009: The spike protein of SARS-CoV--a target for vaccine and therapeutic development[J]. Nat Rev Microbiol, 7, 226-236. doi: 10.1038/nrmicro2090
-
Duan J, Yan X, Guo X, Cao W, Han W, Qi C, Feng J, Yang D, Gao G, Jin G, 2005: A human SARS-CoV neutralizing antibody against epitope on S2 protein[J]. Biochem Biophys Res Commun, 333, 186-193. doi: 10.1016/j.bbrc.2005.05.089
-
Eaton B T, Broder C C, Middleton D, Wang L F, 2006: Hendra and Nipah viruses: different and dangerous[J]. Nat Rev Microbiol, 4, 23-35. doi: 10.1038/nrmicro1323
-
Ekiert D C, Bhabha G, Elsliger M A, Friesen R H, Jongeneelen M, Throsby M, Goudsmit J, Wilson I A, 2009: Antibody recognition of a highly conserved influenza virus epitope[J]. Science, 324, 246-251. doi: 10.1126/science.1171491
-
Ekiert D C, Friesen R H, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse H J, Brandenburg B, Vogels R, Brakenhoff J P, Kompier R, Koldijk M H, Cornelissen L A, Poon L L, Peiris M, Koudstaal W, Wilson I A, Goudsmit J, 2011: A highly conserved neutralizing epitope on group 2 influenza A viruses[J]. Science, 333, 843-850. doi: 10.1126/science.1204839
-
Elshabrawy H A, Coughlin M M, Baker S C, Prabhakar B S, 2012: Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing[J]. PLoS ONE, 7, e50366-. doi: 10.1371/journal.pone.0050366
-
Euler Z, Schuitemaker H, 2012: Cross-reactive broadly neutralizing antibodies: timing is everything[J]. Front Immunol, 3, 215-.
-
Fennell B J, Darmanin-Sheehan A, Hufton S E, Calabro V, Wu L, Muller M R, Cao W, Gill D, Cunningham O, Finlay W J, 2010: Dissection of the IgNAR V domain: molecular scanning and orthologue database mining define novel IgNAR hallmarks and affinity maturation mechanisms[J]. J Mol Biol, 400, 155-170. doi: 10.1016/j.jmb.2010.04.061
-
Fric J, Bertin-Maghit S, Wang C I, Nardin A, Warter L, 2013: Use of human monoclonal antibodies to treat chikungunya virus infection[J]. J Infect Dis, 207, 319-322. doi: 10.1093/infdis/jis674
-
Friedrich B M, Trefry J C, Biggins J E, Hensley L E, Honko A N, Smith D R, Olinger G G, 2012: Potential vaccines and post-exposure treatments for filovirus infections[J]. Viruses, 4, 1619-1650. doi: 10.3390/v4091619
-
Gong R, Chen W, Dimitrov D S, 2012: Candidate antibody-based therapeutics against HIV-1[J]. BioDrugs, 26, 143-162. doi: 10.2165/11631400-000000000-00000
-
Gong R, Wang Y, Ying T, Dimitrov D S, 2012: Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn[J]. PLoS ONE, 7, e42288-. doi: 10.1371/journal.pone.0042288
-
Greenough T C, Babcock G J, Roberts A, Hernandez H J, Thomas W D, J r., Coccia J A, Graziano R F, Srinivasan M, Lowy I, Finberg R W, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan J L, Ambrosino D M, 2005: Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice[J]. J Infect Dis, 191, 507-514. doi: 10.1086/jid.2005.191.issue-4
-
Haynes B F, Kelsoe G, Harrison S C, Kepler T B, 2012: B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study[J]. Nat Biotechnol, 30, 423-433. doi: 10.1038/nbt.2197
-
Higo-Moriguchi K, Akahori Y, Iba Y, Kurosawa Y, Taniguchi K, 2004: Isolation of human monoclonal antibodies that neutralize human rotavirus[J]. J Virol, 78, 3325-3332. doi: 10.1128/JVI.78.7.3325-3332.2004
-
Huang C C, Tang M, Zhang M Y, Majeed S, Montabana E, Stanfield R L, Dimitrov D S, Korber B, Sodroski J, Wilson I A, Wyatt R, Kwong P D, 2005: Structure of a V3-containing HIV-1 gp120 core[J]. Science, 310, 1025-1028. doi: 10.1126/science.1118398
-
Huang C C, Venturi M, Majeed S, Moore M J, Phogat S, Zhang M Y, Dimitrov D S, Hendrickson W A, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong P D, 2004: Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120[J]. Proc Natl Acad Sci U S A, 101, 2706-2711. doi: 10.1073/pnas.0308527100
-
Hwang W C, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco W A, Liddington R C, 2006: Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R[J]. J Biol Chem, 281, 34610-34616. doi: 10.1074/jbc.M603275200
-
Jacobs S A, Diem M D, Luo J, Teplyakov A, Obmolova G, Malia T, Gilliland G L, O'Neil K T, 2012: Design of novel FN3 domains with high stability by a consensus sequence approach[J]. Protein Engineering Design Selection, 25, 107-117. doi: 10.1093/protein/gzr064
-
Kajihara M, Marzi A, Nakayama E, Noda T, Kuroda M, Manzoor R, Matsuno K, Feldmann H, Yoshida R, Kawaoka Y, Takada A, 2012: Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein[J]. J Virol, 86, 13467-13474. doi: 10.1128/JVI.01896-12
-
Kaufmann B, Vogt M R, Goudsmit J, Holdaway H A, Aksyuk A A, Chipman P R, Kuhn R J, Diamond M S, Rossmann M G, 2010: Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354[J]. Proc Natl Acad Sci U S A, 107, 18950-18955. doi: 10.1073/pnas.1011036107
-
Koide A, Wojcik J, Gilbreth R N, Hoey R J, Koide S, 2012: Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold[J]. J Mol Biol, 415, 393-405. doi: 10.1016/j.jmb.2011.12.019
-
Kwong P D, Mascola J R, 2012: Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies[J]. Immunity, 37, 412-425. doi: 10.1016/j.immuni.2012.08.012
-
Kwong P D, Wyatt R, Robinson J, Sweet R W, Sodroski J, Hendrickson W A, 1998: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody[J]. Nature, 393, 648-659. doi: 10.1038/31405
-
KLee J E, Fusco M L, Hessell A J, Oswald W B, Burton D R, Saphire E O, 2008: Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor[J]. Nature, 454, 177-182. doi: 10.1038/nature07082
-
Lee J E, Kuehne A, Abelson D M, Fusco M L, Hart M K, Saphire E O, 2008: Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain[J]. J Mol Biol, 375, 202-216. doi: 10.1016/j.jmb.2007.10.017
-
Li F, Li W, Farzan M, Harrison S C, 2005: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 309, 1864-1868. doi: 10.1126/science.1116480
-
Lindesmith L C, Beltramello M, Donaldson E F, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric R S, 2012: Immunogenetic mechanisms driving norovirus GII.4 antigenic variation[J]. PLoS Pathog, 8, e1002705-. doi: 10.1371/journal.ppat.1002705
-
Marasco W A, Sui J, 2007: The growth and potential of human antiviral monoclonal antibody therapeutics[J]. Nat Biotechnol, 25, 1421-1434. doi: 10.1038/nbt1363
-
Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, Takada A, 2012: Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever[J]. PLoS ONE, 7, e36192-. doi: 10.1371/journal.pone.0036192
-
Meng X, Xiang Y, 2012: Generation and characterization of monoclonal antibodies specific for vaccinia virus[J]. Methods Mol Biol, 890, 219-232. doi: 10.1007/978-1-61779-876-4
-
Meuleman P, Catanese M T, Verhoye L, Desombere I, Farhoudi A, Jones C T, Sheahan T, Grzyb K, Cortese R, Rice C M, Leroux-Roels G, Nicosia A, 2012: A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo[J]. Hepatology, 55, 364-372. doi: 10.1002/hep.24692
-
Migone T S, Subramanian G M, Zhong J, Healey L M, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer S D, 2009: Raxibacumab for the treatment of inhalational anthrax[J]. N Engl J Med, 361, 135-144. doi: 10.1056/NEJMoa0810603
-
Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H, 1993: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1[J]. J Virol, 67, 6642-6647.
-
Nakauchi M, Fukushi S, Saijo M, Mizutani T, Ure A E, Romanowski V, Kurane I, Morikawa S, 2009: Characterization of monoclonal antibodies to Junin virus nucleocapsid protein and application to the diagnosis of hemorrhagic fever caused by South American arenaviruses[J]. Clin Vaccine Immunol, 16, 1132-1138. doi: 10.1128/CVI.00163-09
-
Nikolov D B, Broder C C, and et al. Submitted.
-
Nybakken G E, Oliphant T, Johnson S, Burke S, Diamond M S, Fremont D H, 2005: Structural basis of West Nile virus neutralization by a therapeutic antibody[J]. Nature, 437, 764-769. doi: 10.1038/nature03956
-
Ohta A, Fujita A, Murayama T, Iba Y, Kurosawa Y, Yoshikawa T, Asano Y, 2009: Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner[J]. Microbes Infect, 11, 1029-1036. doi: 10.1016/j.micinf.2009.07.010
-
Oliphant T, Engle M, Nybakken G E, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung K M, Ebel G D, Kramer L D, Fremont D H, Diamond M S, 2005: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus[J]. Nat Med, 11, 522-530. doi: 10.1038/nm1240
-
Pak J E, Sharon C, Satkunarajah M, Auperin T C, Cameron C M, Kelvin D J, Seetharaman J, Cochrane A, Plummer F A, Berry J D, Rini J M, 2009: Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain[J]. J Mol Biol, 388, 815-823. doi: 10.1016/j.jmb.2009.03.042
-
Prabakaran P, Streaker E, Chen W, and Dimitrov D S. 2011. 454 antibody sequencing-error characterization and correction. BMC Research Notes: In Press.
-
Prabakaran P, Gan J, Wu Y Q, Zhang M Y, Dimitrov D S, Ji X, 2006: Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs[J]. J Mol Biol, 357, 82-99. doi: 10.1016/j.jmb.2005.12.062
-
Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov A S, Broder C C, Dimitrov D S, 2009: Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses[J]. Expert Opin Biol Ther, 9, 355-368. doi: 10.1517/14712590902763755
-
Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, Dimitrov D S, 2012: Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing[J]. Front Microbiol, 3, 277-.
-
Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov D S, 2006: Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody[J]. J Biol Chem, 281, 15829-15836. doi: 10.1074/jbc.M600697200
-
Qiu X, Alimonti J B, Melito P L, Fernando L, Stroher U, Jones S M, 2011: Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies[J]. Clin Immunol, 141, 218-227. doi: 10.1016/j.clim.2011.08.008
-
Rani M, Bolles M, Donaldson E F, Van Blarcom T, Baric R, Iverson B, Georgiou G, 2012: Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus[J]. J Virol, 86, 9113-9121. doi: 10.1128/JVI.00233-12
-
Reichert J M, 2008: Monoclonal Antibodies as Innovative Therapeutics[J]. Current Pharmaceutical Biotechnology, 9, 423-430. doi: 10.2174/138920108786786358
-
Saijo M, Tang Q, Shimayi B, Han L, Zhang Y, Asiguma M, Tianshu D, Maeda A, Kurane I, Morikawa S, 2005: Antigen-capture enzyme-linked immunosorbent assay for the diagnosis of crimean-congo hemorrhagic fever using a novel monoclonal antibody[J]. J Med Virol, 77, 83-88. doi: 10.1002/(ISSN)1096-9071
-
Sanchez M D, Pierson T C, McAllister D, Hanna S L, Puffer B A, Valentine L E, Murtadha M M, Hoxie J A, Doms R W, 2005: Characterization of neutralizing antibodies to West Nile virus[J]. Virology, 336, 70-82. doi: 10.1016/j.virol.2005.02.020
-
Schrama D, Reisfeld R A, Becker J C, 2006: Antibody targeted drugs as cancer therapeutics[J]. Nature Reviews Drug Discovery, 5, 147-159. doi: 10.1038/nrd1957
-
Scott L J, Lamb H M, 1999: Palivizumab[J]. Drugs, 58, 305-311. doi: 10.2165/00003495-199958020-00009
-
Shedlock D J, Bailey M A, Popernack P M, Cunningham J M, Burton D R, Sullivan N J, 2010: Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms[J]. Virology, 401, 228-235. doi: 10.1016/j.virol.2010.02.029
-
Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H, 2001: A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1[J]. Aids Research and Human Retroviruses, 17, 1757-1765. doi: 10.1089/08892220152741450
-
Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik D L, Chen L, Weiss R, de Haard H, Verrips T, 2012: Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C[J]. PLoS ONE, 7, e33298-. doi: 10.1371/journal.pone.0033298
-
Sui J, Hwang W C, Perez S, Wei G, Aird D, Chen L M, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox N J, Bankston L A, Donis R O, Liddington R C, Marasco W A, 2009: Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses[J]. Nat Struct Mol Biol, 16, 265-273. doi: 10.1038/nsmb.1566
-
ter Meulen J, van den Brink E N, Poon L L, Marissen W E, Leung C S, Cox F, Cheung C Y, Bakker A Q, Bogaards J A, van Deventer E, Preiser W, Doerr H W, Chow V T, de Kruif J, Peiris J S, Goudsmit J, 2006: Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants[J]. PLoS Med, 3, e237-. doi: 10.1371/journal.pmed.0030237
-
Throsby M, van den Brink E, Jongeneelen M, Poon L L, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J, 2008: Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells[J]. PLoS ONE, 3, e3942-. doi: 10.1371/journal.pone.0003942
-
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo M R, Murphy B R, Rappuoli R, Lanzavecchia A, 2004: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus[J]. Nature Medicine, 10, 871-875. doi: 10.1038/nm1080
-
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore J P, Katinger H, 1996: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1[J]. J Virol, 70, 1100-1108.
-
van Boheemen S, de Graaf M, Lauber C, Bestebroer T M, Raj V S, Zaki A M, Osterhaus A D, Haagmans B L, Gorbalenya A E, Snijder E J, and Fouchier R A. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio, 3.
-
van Gils M J, Sanders R W, 2013: Broadly neutralizing antibodies against HIV-1: templates for a vaccine[J]. Virology, 435, 46-56. doi: 10.1016/j.virol.2012.10.004
-
Verkoczy L, Kelsoe G, Moody M A, Haynes B F, 2011: Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies[J]. Curr Opin Immunol, 23, 383-390. doi: 10.1016/j.coi.2011.04.003
-
Waldmann T A, 2003: Immunotherapy: past, present and future[J]. Nature Medicine, 9, 269-277. doi: 10.1038/nm0303-269
-
Weiner L M, Dhodapkar M V, Ferrone S, 2009: Monoclonal antibodies for cancer immunotherapy[J]. Lancet, 373, 1033-1040. doi: 10.1016/S0140-6736(09)60251-8
-
Whittle J R, Zhang R, Khurana S, King L R, Manischewitz J, Golding H, Dormitzer P R, Haynes B F, Walter E B, Moody M A, Kepler T B, Liao H X, Harrison S C, 2011: Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin[J]. Proc Natl Acad Sci U S A, 108, 14216-14221. doi: 10.1073/pnas.1111497108
-
Wilson J A, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn A L, Hart M K, 2000: Epitopes involved in antibody-mediated protection from Ebola virus[J]. Science, 287, 1664-1666. doi: 10.1126/science.287.5458.1664
-
Xiao X, Feng Y, Vu B K, Ishima R, Dimitrov D S, 2009: A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors[J]. Biochem Biophys Res Commun, 387, 387-392. doi: 10.1016/j.bbrc.2009.07.044
-
Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang M Y, Longo N S, Dimitrov D S, 2009: Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens[J]. Biochem Biophys Res Commun, 390, 404-409. doi: 10.1016/j.bbrc.2009.09.029
-
Xiao X D, Chen W Z, Feng Y, Dimitrov D S, 2009: Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies[J]. Viruses-Basel, 1, 802-817. doi: 10.3390/v1030802
-
Xu K, Rajashankar K R, Chan Y P, Himanen J P, Broder C C, Nikolov D B, 2008: Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3[J]. Proc Natl Acad Sci U S A, 105, 9953-9958. doi: 10.1073/pnas.0804797105
-
Yang Z Y, Werner H C, Kong W P, Leung K, Traggiai E, Lanzavecchia A, Nabel G J, 2005: Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses[J]. Proc Natl Acad Sci U S A, 102, 797-801. doi: 10.1073/pnas.0409065102
-
Ye J Q, Shao H X, Perez D R, 2012: Passive immune neutralization strategies for prevention and control of influenza A infections[J]. Immunotherapy, 4, 175-186. doi: 10.2217/imt.11.167
-
Ying T, Chen W, Gong R, Feng Y, Dimitrov D S, 2012: Soluble monomeric IgG1 Fc[J]. J Biol Chem, 287, 19399-19408. doi: 10.1074/jbc.M112.368647
-
Zhang M Y, Choudhry V, Xiao X, Dimitrov D S, 2005: Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS[J]. Curr Opin Mol Ther, 7, 151-156.
-
Zhang M Y, Xiao X, Sidorov I A, Choudhry V, Cham F, Zhang P F, Bouma P, Zwick M, Choudhary A, Montefiori D C, Broder C C, Burton D R, Quinnan G V, J r., and Dimitrov D S, 2004: Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody[J]. J Virol, 78, 9233-9242. doi: 10.1128/JVI.78.17.9233-9242.2004
-
Zhu Z, Bossart K N, Bishop K A, Crameri G, Dimitrov A S, McEachern J A, Feng Y, Middleton D, Wang L F, Broder C C, Dimitrov D S, 2008: Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody[J]. J Infect Dis, 197, 846-853. doi: 10.1086/587999
-
Zhu Z, Dimitrov A S, Bossart K N, Crameri G, Bishop K A, Choudhry V, Mungall B A, Feng Y R, Choudhary A, Zhang M Y, Feng Y, Wang L F, Xiao X, Eaton B T, Broder C C, Dimitrov D S, 2006: Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies[J]. J Virol, 80, 891-899. doi: 10.1128/JVI.80.2.891-899.2006
-
Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley L E, Prabakaran P, Rockx B, Sidorov I A, Corti D, Vogel L, Feng Y, Kim J O, Wang L F, Baric R, Lanzavecchia A, Curtis K M, Nabel G J, Subbarao K, Jiang S, Dimitrov D S, 2007: Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies[J]. Proc Natl Acad Sci U S A, 104, 12123-12128. doi: 10.1073/pnas.0701000104
-
Zhu Z, Qin H R, Chen W, Zhao Q, Shen X, Schutte R, Wang Y, Ofek G, Streaker E, Prabakaran P, Fouda G G, Liao H X, Owens J, Louder M, Yang Y, Klaric K A, Moody M A, Mascola J R, Scott J K, Kwong P D, Montefiori D, Haynes B F, Tomaras G D, Dimitrov D S, 2011: Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies[J]. J Virol, 85, 11401-11408. doi: 10.1128/JVI.05312-11